Jardiance Cost in Nebraska 2026: Prices, Insurance, Medicaid, and Compounding

What Does Jardiance Actually Cost in Nebraska?

Jardiance carries a manufacturer list price of approximately $680 per month in Nebraska retail settings in 2026, with little variation between Omaha, Lincoln, and rural pharmacies. Most commercially insured patients pay far less after their plan's negotiated rate and copay, but uninsured or underinsured Nebraskans face the full cash price unless they use a savings program or an alternative source such as a compounding pharmacy.

The gap between list price and what a patient actually pays depends on three factors: their insurance tier placement for empagliflozin, their plan's cost-sharing structure, and whether they qualify for the Boehringer Ingelheim/Lilly savings card. A 2023 JAMA Internal Medicine analysis found that among brand-name SGLT-2 inhibitors, the average out-of-pocket cost after insurance was $42 per month for commercially insured patients, compared with $496 per month for uninsured patients filling the same prescription at retail. [1]

The FDA approved empagliflozin 10 mg and 25 mg tablets for type 2 diabetes in 2014, and the approved prescribing information is available through the FDA's drug database. [2] Because Jardiance remains brand-only with no FDA-approved generic equivalent as of early 2025, price competition at the generic level does not yet exist for Nebraska patients.

GoodRx and similar discount platforms list empagliflozin (Jardiance) at $620 to $695 at major Nebraska chains such as Walgreens, CVS, and Walmart in early 2025, depending on the specific coupon applied. These coupons cannot be combined with insurance. Patients should compare the GoodRx price against their insurer's negotiated price before deciding which to use at the counter.

Nebraska Medicaid Coverage of Jardiance: What the Formulary Says

Nebraska Medicaid (administered through the Nebraska Department of Health and Human Services and its managed-care partners) does not cover Jardiance as a standard formulary benefit in 2025. [3] Empagliflozin does not appear on the Nebraska Medicaid preferred drug list for any of its currently approved indications, including type 2 diabetes, heart failure with reduced ejection fraction, or chronic kidney disease.

Patients enrolled in Nebraska Medicaid who need an SGLT-2 inhibitor may request a prior authorization exception, though approvals are rare given the formulary exclusion. The American Diabetes Association's 2024 Standards of Care recommend SGLT-2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of glycemic control, a position that can support a medical-necessity argument. [4] Nebraska's Medicaid program has not yet aligned its formulary with that recommendation for empagliflozin specifically.

Dual-eligible patients (Medicare/Medicaid) may have a different pathway. Medicare Part D plans vary in their tier placement of Jardiance; some plans cover it on Tier 3 with a copay of $45 to $85 per month in the coverage phase, while others exclude it. Patients should use Medicare's Plan Finder tool to compare Part D plans in their ZIP code before enrollment or during open enrollment each fall.

The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001). [5] The EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in kidney disease progression or cardiovascular death with empagliflozin vs. placebo. [6] These outcomes data strengthen a prior authorization argument, but Nebraska Medicaid has not formally published a pathway for empagliflozin exceptions at the time of this article's review.

Is Compounded Empagliflozin Legal in Nebraska?

Compounded empagliflozin is available through state-licensed 503A compounding pharmacies in Nebraska. Federal law under Section 503A of the Food, Drug, and Cosmetic Act permits licensed compounding pharmacies to prepare empagliflozin formulations for individual patients who have a valid prescription, provided the drug is not on the FDA's list of drugs that may not be compounded. [7] As of early 2025, empagliflozin is not on that prohibited list.

Nebraska compounds must hold a state pharmacy license issued by the Nebraska Department of Health and Human Services Division of Public Health. [8] Compounding pharmacies operating in Nebraska are also subject to inspection under the Drug Quality and Security Act. Patients and prescribers should verify that any 503A pharmacy filling a compounded empagliflozin prescription is licensed both federally (with the DEA, where applicable) and with the Nebraska pharmacy board.

A practical framework for Nebraska prescribers evaluating compounded empagliflozin:

1. Confirm the patient has a documented clinical indication (type 2 diabetes, heart failure, or CKD) supported by lab values or imaging in the chart.
2. Verify the 503A pharmacy's Nebraska license at the state board website before transmitting the prescription.
3. Document the medical rationale for compounding versus the brand product, particularly if the patient's insurer later requests records.
4. Set a 90-day follow-up to assess glycemic, cardiac, or renal endpoints so the compound's clinical effect can be compared against the branded-drug trial benchmarks.

Compounded empagliflozin prices vary widely by pharmacy. Some Nebraska-accessible 503A pharmacies quote $60 to $150 per month for a 10 mg daily formulation, though pricing is not publicly standardized. Patients should request a written cost estimate before filling. The FDA has not evaluated the purity, potency, or bioequivalence of compounded empagliflozin against the brand product. [9] That uncertainty is clinically relevant: EMPA-REG OUTCOME (N=7,020) used the brand formulation manufactured under full GMP conditions, and extrapolating those cardiovascular outcomes to a compounded preparation requires caution. [10]

Clinical Evidence Supporting Empagliflozin Prescribing

Empagliflozin's evidence base spans three landmark outcome trials, each relevant to the populations Nebraska clinicians most commonly treat.

EMPA-REG OUTCOME (N=7,020) enrolled adults with type 2 diabetes and established cardiovascular disease. At a median follow-up of 3.1 years, empagliflozin reduced the rate of the primary three-point MACE outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 14% vs. placebo (HR 0.86 to 95% CI 0.74 to 0.99, P=0.04 for superiority). [10] Cardiovascular death specifically fell by 38%. The New England Journal of Medicine published these results in 2015, and they formed the basis for the FDA's cardiovascular risk-reduction indication.

EMPEROR-Preserved (N=5,988) extended empagliflozin's benefit to heart failure with preserved ejection fraction. The primary composite outcome of cardiovascular death or heart failure hospitalization was reduced by 21% vs. placebo (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001). [11] This trial was notable because it covered a heart failure phenotype with historically few pharmacologic options.

EMPA-KIDNEY (N=6,609), published in the New England Journal of Medicine in 2023, showed that empagliflozin reduced the progression of kidney disease or cardiovascular death by 28% vs. placebo (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001). [6] The benefit held across patients with and without diabetes, broadening the potential Nebraska patient population who may benefit.

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, an SGLT-2 inhibitor with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of baseline HbA1c." [4] That language directly supports prescribing empagliflozin in high-risk Nebraska patients even when glycemic control is already adequate.

Which Insurance Plans Cover Jardiance in Nebraska?

Commercial insurance coverage of Jardiance in Nebraska follows national formulary structures set by pharmacy benefit managers. The three largest PBMs managing Nebraska employer plans are Express Scripts, CVS Caremark, and OptumRx. Each places empagliflozin on a different tier depending on the specific plan contract.

On Express Scripts' standard national formulary, Jardiance is a Tier 3 preferred brand, which typically carries a copay of $50 to $90 per 30-day supply. [12] CVS Caremark's commercial formularies vary more widely, with some plans placing empagliflozin on Tier 3 and others on a non-preferred Tier 4 at $80 to $120 per fill. OptumRx similarly shows plan-level variation. Nebraska employees covered under self-funded employer plans may have entirely custom formularies that do not follow these standard structures.

ACA Marketplace plans sold on the Nebraska exchange (Healthcare.gov) must cover prescription drugs, but formulary tier placement is insurer-specific. Patients buying a plan during open enrollment should filter plan options by their specific drug list using Healthcare.gov's drug comparison tool, entering "empagliflozin" or "Jardiance" directly. A Bronze plan with a higher deductible may require paying the full negotiated price until the deductible is met, while a Gold plan with a flat copay structure often results in lower per-fill costs for maintenance medications like empagliflozin.

Nebraska's largest commercial carriers, including Blue Cross and Blue Shield of Nebraska and Medica, publish their drug formularies online. Patients can search "Jardiance" or NDC 0597-0149 on those portals to see their specific cost-sharing obligation before filling. [13]

How the Boehringer Ingelheim / Lilly Jardiance Savings Card Works in Nebraska

The Jardiance savings card, co-administered by Boehringer Ingelheim and Eli Lilly, reduces the monthly cost for eligible commercially insured Nebraska patients to as low as $10 per 30-day fill. The program is available at BI's patient assistance portal and applies to patients with private or commercial insurance who are not enrolled in a federally funded program (Medicare, Medicaid, TRICARE, or VA). [14]

Eligibility is automatic for most commercially insured patients. The prescriber writes the prescription normally; the patient downloads or prints the savings card and presents it at the pharmacy alongside their insurance card. The card covers the difference between what insurance pays and $10, up to a maximum annual benefit of $3,500 (program terms as of 2025; confirm current limits at the BI website).

Patients without insurance cannot use the savings card at its $10 tier but may qualify for the Boehringer Ingelheim Cares Foundation patient assistance program, which provides free Jardiance to qualifying low-income, uninsured patients. [14] Household income thresholds apply; Nebraska patients with an income at or below 400% of the federal poverty level may qualify. The 2025 FPL for a single individual is $15,060, making the 400% threshold $60,240.

Getting a Jardiance Prescription via Telehealth in Nebraska

Telehealth prescribing of Jardiance is fully permitted in Nebraska. The state does not impose additional restrictions on teleclinician prescribing of non-controlled oral medications beyond the standard requirements for a valid prescriber-patient relationship and a medical evaluation. [15]

Nebraska enacted telehealth parity legislation requiring commercial insurers to cover telehealth visits at the same rate as in-person visits for covered services. A telehealth provider who conducts a clinical evaluation (reviewing HbA1c, eGFR, urine albumin-to-creatinine ratio, and cardiovascular history) can prescribe empagliflozin to a Nebraska patient and send the prescription electronically to any licensed Nebraska pharmacy, including mail-order pharmacies.

HealthRX-affiliated clinicians follow the ADA's 2024 Standards of Care when evaluating Nebraska patients for empagliflozin. Before prescribing, they review: baseline eGFR (empagliflozin should not be initiated if eGFR is <20 mL/min/1.73m2 per the current FDA label), [2] urinalysis to screen for recurrent UTI history, and any prior history of diabetic ketoacidosis given the small risk of euglycemic DKA with SGLT-2 inhibitors. [16]

Patients with eGFR between 20 and 45 mL/min/1.73m2 may still receive empagliflozin for its cardiorenal protective effects even though the glucose-lowering effect is attenuated at that renal function level, a nuance confirmed by the EMPA-KIDNEY subgroup analyses. [6] Telehealth clinicians should document eGFR at initiation and recheck at 3 months to confirm stability.

Practical Cost-Reduction Strategies for Nebraska Patients in 2026

Several concrete steps can reduce what a Nebraska patient pays for empagliflozin in 2026.

First, check whether the Boehringer Ingelheim savings card applies. Commercially insured patients who qualify pay $10 per month, which is the lowest accessible price for the brand product. [14]

Second, compare GoodRx against insurance at every fill. Prices shift quarterly, and a GoodRx coupon at a specific Nebraska pharmacy may beat the insurance copay during certain periods, particularly for patients on high-deductible plans who have not yet met their deductible.

Third, ask about mail-order pricing. Most Nebraska PBMs offer a 90-day supply at a discounted effective monthly rate compared with 30-day fills. A Tier 3 copay of $70 per 30-day fill may become $140 for 90 days through mail-order, cutting the effective monthly cost to $47.

Fourth, evaluate compounded empagliflozin through a licensed 503A pharmacy if cost remains prohibitive. A prescriber at HealthRX can assess whether a compounded formulation is clinically appropriate given the patient's indication and baseline labs, and can document the rationale in the chart for audit purposes.

Fifth, apply for BI Cares Foundation assistance if the patient is uninsured and meets income criteria. Applications require proof of income, a prescription, and a completed enrollment form submitted through the foundation's portal. [14]

The CREDENCE trial (N=4,401) of canagliflozin, a related SGLT-2 inhibitor, showed a 30% reduction in the primary renal composite endpoint vs. placebo in patients with type 2 diabetes and CKD (HR 0.70 to 95% CI 0.59 to 0.82, P<0.001), [17] context that supports why Nebraska prescribers and Medicaid administrators should weigh the long-term cost offset of preventing dialysis initiation against the short-term drug acquisition cost. A single year of in-center hemodialysis carries a Medicare-estimated cost of approximately $96,000 per patient annually. [18]

Safety Monitoring for Nebraska Patients Taking Empagliflozin

Empagliflozin carries a class-level FDA boxed warning for an increased risk of lower-limb amputation (seen with canagliflozin in CANVAS but not confirmed with empagliflozin in EMPA-REG OUTCOME). [2] Nebraska prescribers should still conduct routine foot exams and document peripheral vascular status at initiation and annually.

Genital mycotic infections occur in approximately 5.4% of women and 3.1% of men taking empagliflozin vs. 1.5% and 0.6% on placebo, based on EMPA-REG OUTCOME safety data. [10] Patients should be counseled at the first prescription fill. Fournier's gangrene (necrotizing fasciitis of the perineum) is rare but has been reported with the SGLT-2 class; the FDA added a warning in 2018. [2]

Volume depletion and hypotension are relevant for older Nebraska patients on concurrent loop diuretics. The FDA label recommends assessing volume status before initiating empagliflozin in patients on diuretics or with low systolic blood pressure. [2] Euglycemic DKA, though uncommon, may occur even with blood glucose <250 mg/dL; patients undergoing surgery or prolonged fasting should hold empagliflozin 3 to 4 days before the procedure per the AACE 2023 perioperative guidelines. [16]